VEGF (Bevacizumab) Recombinant Human Monoclonal Antibody (A4.6.1), Functional Grade, Fc Muted™, Leinco Technologies™

Description

• Specificity: This non-therapeutic biosimilar antibody uses the same variable region sequence as the therapeutic antibody Bevacizumab
• Bevacizumab recognizes both native and reduced human VEGF (isoform 165)
• Endotoxin Level: <1.0 EU/mg as determined by the LAL method
• Purity: ≥95% monomer by analytical SEC
• Preparation: Functional grade preclinical antibodies are manufactured in an animal free facility using in vitro cell culture techniques and are purified by a multi-step process including the use of protein A or G to assure extremely low levels of endotoxins, leachable protein A or aggregates
• Pathogen Testing: To protect mouse colonies from infection by pathogens and to assure that experimental preclinical data is not affected by such pathogens, all of Leinco recombinant biosimilar antibodies are tested and guaranteed to be negative for all pathogens in the IDEXX IMPACT I Mouse Profile
• Storage: Functional grade biosimilar antibodies may be stored sterile as received at 2-8C for up to one month
• For longer term storage, aseptically aliquot in working volumes without diluting and store at -80C
• Avoid Repeated Freeze Thaw Cycles
• VEGF (Bevacizumab) Recombinant Monoclonal antibody specifically detects VEGF (Bevacizumab) in Human samples
• It is validated for ELISA, Flow Cytometry, Immunoprecipitation, Inhibition Assays, Neutralization, Western Blot